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Abstract
Background: To evaluate feasibility and preliminary outcomes associated with sequential whole abdomen
irradiation (WAI) as consolidative treatment following comprehensive surgery and systemic chemotherapy for
advanced endometrial cancer.
Methods: We conducted a retrospective analysis of patients treated at our institution from 2000 to 2011. Inclusion
criteria were stage III-IV endometrial cancer patients with histological proof of one or more sites of extra-uterine
abdomen-confined disease, treated with WAI as part of multimodal therapy. Endpoints were feasibility, acute
toxicity, late effects, recurrence-free survival (RFS) and overall survival (OS). Twenty patients were identified.
Chemotherapy consisted of 3 to 6 cycles of a platinum-paclitaxel regimen in 18 patients. WAI was delivered using
conventional technique to a median total dose of 27.5 Gy.
Results: No grade 4 toxicities occurred during chemotherapy or radiotherapy. No radiation dose reduction was
necessary. Three patients developed small bowel obstruction, all in the context of recurrent intraperitoneal disease.
Kaplan-Meier estimates and 95% confidence intervals for RFS and OS at one year were 63% (38–80%) and 83%
(56-94%) and at 3 years 57% (33-76%) and 62% (34-81%), respectively. On univariate Cox analysis, stage IVB and
serous papillary (SP) histology were found to be statistically significantly (at the p= 0.05 level) associated with worse
RFS and OS. The peritoneal cavity was the most frequent site of initial failure.
Conclusions: Consolidative WAI following chemotherapy is feasible and can be performed without interruption
with manageable acute and late toxicity. Patients with endometrioid adenocarcinoma, especially stage FIGO III, had
favorable outcomes possibly meriting prospective evaluation of the addition of WAI following chemotherapy in
selected patients. Patients with SP do poorly and do not routinely benefit from this approach.
Keywords: Whole abdomen irradiation, Advanced endometrial cancer, Chemotherapy, Radiotherapy
Background
Endometrial cancer (EC) is the most common malig-
nancy of the female genital tract in the United States
with an estimated 47,100 new cases and 8,000 deaths in
2012 [1]. Most patients are diagnosed with early stage
disease and have an excellent prognosis. However, for
the <20% of patients presenting with extra-uterine dis-
ease (stages III and IV), the 5-year overall survival (OS)
rates decrease dramatically and range from 30-89% to
0-20%, respectively [2-5]. Optimal management for these
patients remains undefined.
Gynecologic Oncology Group (GOG) protocol 122 pro-
spectively randomized patients between chemotherapy
and whole abdomen irradiation (WAI), and established
the superiority of systemic chemotherapy [5]. As a conse-
quence, WAI is generally no longer recommended in the
postoperative treatment of patients with stage III or IV
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ment arms of GOG 122. More than half of the patients
progressed or failed in the abdomen illustrating the need
for further therapeutic improvements in this high-risk pa-
tient population.
A predilection for diffuse peritoneal spread is the ration-
ale for the use of whole abdomen irradiation (WAI), which
appeared to have provided therapeutic benefit in both
retrospective and prospective studies including patients
with proven peritoneal dissemination [5-10]. It is logical to
speculate that adding WAI following chemotherapy may
result in superior survival outcomes by improving regional
control. Recent studies have reported encouraging prelim-
inary results of multimodal treatment, but have included
few patients treated with WAI [11-14].
We sought to review outcomes of WAI as part of
multimodal post surgical treatment of women with
abdomen-confined advanced EC at Massachusetts
General Hospital (MGH).
Methods
Patient identification and data collection
After obtaining approval from the MGH Institutional
Review Board, we conducted a single-institution retro-
spective review of feasibility, toxicity and outcomes. Pa-
tients were identified using our tumor registry to meet
following the inclusion criteria: patients with locally ad-
vanced histologically confirmed EC with histologic proof
of one or more sites of abdomen-confined extra-uterine
disease, who underwent primary surgery followed by
multimodal chemotherapy and radiotherapy including
WAI between 2000 and 2011.
Exclusion criteria were the presence of known residual
macroscopic disease at the time of consolidation WAI,
the presence of metastasis beyond the abdomen, recur-
rence after prior treatment or a different histology than
endometrioid adenocarcimona (EAC), serous papillary
(SP) or clear cell (CC) carcinoma. Patients were also ex-
cluded if they had a FIGO 1988 stage IIIA disease based
on positive cytology only.
Complete clinical data were abstracted by review of
operative notes, and both hospital and outpatient chart.
Toxicity was assessed using Common Terminology Cri-
teria for Adverse Events CTCAE version 4.03 (2010).
Consent
Written informed consent was obtained from the pa-
tients for the publication of this report.
Patient and treatment characteristics
A total of 20 patients were included in the study. Patient
and treatment characteristics are listed in Table 1. Primary
surgery procedure included comprehensive surgical staging
and cytoreductive surgery with at least total abdominal
hysterectomy, bilateral salpingo-oophorectomy, debulking
of gross disease and peritoneal cytology in all patients.
Lymph node dissection or sampling was performed in 17
patients (85%), either pelvic only (n=8) or both pelvic and
para-aortic (n=9). Workup for disease extent included a
CT-scan of the pelvis, abdomen and chest for all patients.
Adjuvant chemotherapy as part of a multimodal treat-
ment was recommended in all 20 patients by a multi-
disciplinary tumor board. However, 2 patients did not
receive chemotherapy for the following reasons: patient
refusal (n =1) and medical contraindications (n =1) in a
patient with severe diabetes and organ damage. Both
were included in this study as an intent-to-treat analysis.
Adjuvant chemotherapy consisted of 3 to 6 cycles intra-
venous Paclitaxel (T) and Carboplatin (P) based chemo-
therapy on a q21 day schedule.
A total of 5 patients had postoperative macroscopic
residual disease. None of the patients had demon-
strable macroscopic residual disease at the time of
radiotherapy. Three patients had been considered sub
optimally debulked in the surgical report. After com-
pletion of chemotherapy, they underwent a 2
nd-look
laparoscopy that showed no evidence of persistent dis-
ease in one case and microscopic foci of residual dis-
ease in two cases. Two patients considered as optimally
debulked had [18 F]-fluorodeoxyglucose (FDG) uptakes
compatible with residual disease in a postoperative
FDG-Positron Emission Tomography/Computed Tom-
ography (PET/CT) using contrast enhanced diagnostic
quality CT. After completion of chemotherapy, subse-
quent PET/CT scan showed near complete resolution
of the areas of abnormal uptake.
WAI was administered following completion of che-
motherapy and after hematologic toxicity recovered to
an acceptable level. Median time between between com-
pletion of chemotherapy and onset of radiotherapy was
48 days (range, 21–104 days). The whole abdomen was
treated based on a computer tomography simulation using
anterior-posterior/postero-anterior (ap/pa) extended skin
surface distance (SSD) opposed fields (6 to 18 MV pho-
tons) to a total dose ranging from 20 to 30 Gy (median
27.5). The daily fraction size was 1.0 -1.25 Gy, 5 days per
week using 6 to 18 MV photons. One patient was treated
1.0 Gy twice-a-day (b.i.d.). Kidneys and liver shielding was
used to maintain the total dose ≤18 Gy for the kidneys
and ≤22 Gy for the liver.
Eleven patients (55%) received a subsequent pelvic
boost volume (boost), which was combined with an ex-
tended para-aortic field in 9 cases (45%). Indication for
ab o o s tw a s :t h ep r e s e n c eo fn o d a lm e t a s t a s e s( n = 6 ) ,
stage IVB disease with aggressive histology and un-
known nodal status (n= 1), postoperative PET-positive
residual pelvic lymph node (n=1) and stage IVB disease
in a patient who had refused chemotherapy (n=1).
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planned ap/pa opposed fields using 6–23 MV photons
to a median total dose of 19.2 Gy (range, 18.0 – 28.3) in
1.6 to 1.8 Gy daily fractions. Two patients with para-
aortic nodal involvement were given additional
involved-field boost to the para-aortic area at risk. The
total cumulative external beam doses to the pelvis
ranged between 44.8 to 48 Gy (median 46.7 Gy) and be-
tween 44.8 to 55.7 Gy for the para-aortic region (me-
dian 46.7 Gy). One patient received the involved field
boost treatment prior to WAI because of concerns re-
garding hematologic tolerance. All patients except one
received the entire radiotherapy treatment at MGH af-
filiated facilities.
An additional Ir192-High Dose Rate vaginal cuff
brachytherapy was performed in 17 cases to a median
total dose of 18 Gy (range, 13–21 Gy) in a median of 3
fractions (range, 3–5 fractions). Dose was prescribed to
the applicator surface.
Upon treatment completion patients were evaluated at
regular intervals at MGH facilities. Imaging was performed
in any patient with current recurrence suspected on the
basis of symptoms or physical examination, but was not
Table 1 Patients’ and treatment characteristics (n= 20)
Category Distribution
and%
Age (median, range) 61 (34–77)
2009 FIGO stage
IIIA 7 (35%)
IIIC 5 (25%)
IIIC1 2 (10%)
IIIC2 3 (15%)
IVB 7 (35%)
No classification available * 1 (5%)
Histology
Endometrioid (pure) 13 (65%)
Papillary serous (pure) 4 (20%)
Papillary serous (mixed) 3 (15%)
Grade
1 3 (15%)
2 7 (35%)
3 10 (50%)
Nodal status
pN0 11 (55%)
pN+ 6 (30%)
pNx 3 (15%)
Peritoneal cytology
Positive or suspicious for malignant cells 15 (75%)
Negative 4 (20%)
Not done 1 (5%)
SURGERY
Surgical approach
Laparotomy 15 (75%)
Laparoscopy 5 (25%)
Lymph node dissection performed 17 (85%)
Pelvic only 8 (40%)
Pelvic+ PA 9 (45%)
Total number of dissected LN (median, range) 18 (3–46)
CHEMOTHERAPY
Number of cycles (received/planned)
0/6 cycles 2 (10%)
3/3 cycles 2 (10%)
4/6 cycles 1 (5%)
5/6 cycles 1 (5%)
6/6 cycles 14 (70%)
Drug combination (n=18)
TP 14 (78%)
TAP 4 (22%)
Table 1 Patients’ and treatment characteristics (n= 20)
(Continued)
RADIOTHERAPY
WAI total dose (median, range)
Total dose (Gy) 27.5 (20–30)
Daily dose (Gy) 1.25 (1.0 - 1.25
Additional volume (boost)
Pelvic only 7 (35%)
Pelvic + PA 2 (10%)
Cumulative total dose(median, range)
Pelvis (Gy) 46.7 (44.8 - 48)
PA (Gy) 46.7 (44.8 - 55.7)
Vaginal cuff brachytherapy 17 (85%)
Dose (median, range)
Total dose (Gy) 18 (13–21)
Number of fractions 3 (3–5)
TIMING (median, range)
Between surgery and chemo start (days) 24 (9–48)
Between end of chemo and RT start (days) 48 (21–104)
Between surgery and completion of all treatments
(months)
5.7 (1.5 - 7.6)
Duration of RT (elapsed days) 35 (11–55)
*multifocal cancer arising from endometriosis.
Abbreviations: Chemo Chemotherapy, LN Lymph nodes, PA Para-aortic,
RT Radiotherapy, TP Paclitaxel (175 mg/m
2) and Carboplatin (Area under the
Curve [AUC] 5); TAP = Paclitaxel (175 mg/m
2), Doxorubicin (45 mg/m2) and
Carboplatin (AUC5).
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physical examination.
Statistics
Recurrence-free survival (RFS) and OS estimates were
calculated by Kaplan-Meier (KM) actuarial method
from date of completion of all treatments and reported
for 1, 3 and 5 years. OS times were calculated to date
of death or were censored at date of last documented
contact for patients still alive at time of analysis. RFS
times were calculated to date of first known progres-
sion or death, or were censored at the date of last
contact for patients still alive and who have not
progressed.
Univariate Cox analysis was performed for following
covariates: age at diagnosis (continuous variable), hist-
ology (EAC vs. SP), stage of disease (III vs. IVB), pelvic
and/or para-aortic nodal involvement (yes vs. no), pres-
ence of residual disease after surgery, presence of
residual disease after chemotherapy, completion of
chemotherapy (complete and full dose vs. incomplete or
reduced dose), pelvic boost (yes vs. no), para-aortic
boost (yes vs. no), WAI total dose (continuous variable),
elapsed time between end of chemotherapy and start of
radiotherapy (continuous variable). Significance was de-
fined as a p value <0.05.
All analyses were performed using StataCorp. 2011
(Stata Statistical Software: Release 12. College Station,
TX: StataCorp LP).
Results
Feasibility and acute toxicity
No CTCAE grade 4 side effects were observed during
chemotherapy or radiotherapy. Overall hematologic tox-
icity and elevation of liver enzymes are summarized in
Table 2. During chemotherapy, 4 patients required some
dose reduction for the following reasons: CTC grade 3
neuropathy and/or myalgia (n =2) and CTC grade 3 fe-
brile neutropenia (n= 2). Two patients required blood
transfusions and 6 required Granulocyte-Colony Sti-
mulating Factor (G-CSF) during chemotherapy but none
required G-CSF during radiotherapy. Overall, acute tox-
icity was manageable with most patients experiencing
CTCAE grade 1–2 fatigue, neuropathy and/or nausea
during chemotherapy and CTCAE grade 1–2 nausea
and/or diarrhea that responded to symptomatic medica-
tion during radiotherapy.
Radiotherapy could be completed as planned in all
the patients without toxicity-related interruptions or
Table 2 Hematologic toxicities (nadir) and elevation of liver enzymes (peak) during treatment
N/A Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
During chemotherapy (n= 18)
Elevation ALT 4 (22%) 9 (50%) 5 (28%) 0 0 0
Elevation AST 5 (28%) 10 (56%) 3 (17%) 0 0 0
Anemia (Hgb) 2 (11%) 3 (17%) 9 (50%) 4 (22%) 0 0
Thrombocytopenia 2 (11%) 13 (72%) 2 (11%) 1 (6%) 0 0
Neutropenia 2 (11%) 12 (67%) 0 2 (11%) 2 (11%)* 0
During RT (n=20)
Elevation ALT 5 (25%) 11 4 (20%) 2 (10%) 0 0
Elevation AST 5 (25%) 11 4 (20%) 0 0 0
Anemia (Hgb) 0 3 (15%) 10 (50%) 6 (30%) 1 (5%) 0
Thrombocytopenia 0 5 (25%) 10 (50%) 4 (20%) 1(5%) 0
Neutropenia 2 (10%) 6 (30%) 6 (30%) 4 (20%) 2 (10%) 0
Hypokalemia 6 (30%) 6 (30%) 1 (5%) 3 (15%) 4 (20%) 0
6 weeks after RT (n=20)
Elevation ALT 9 (45%) 5 (25%) 5 (25%) 0 1 (5%) 0
Elevation AST 9 (45%) 5 (25%) 5 (25%) 0 1 (5%) 0
Anemia (Hgb) 6 (30%) 3 (15%) 8 (40%) 3 (15%) 0 0
Thrombocytopenia 6 (30%) 7 (35%) 5 (25%) 1 (5%) 1 (5%) 0
Neutropenia 7 (35%) 9 (45%) 1 (5%) 2 (10%) 1 (5%) 0
Common terminology criteria for adverse events (CTCAE) version 4.03 (2010).
* febrile neutropenia.
Abbreviations: N/A Information not available at time of analysis, RT Radiotherapy; Hgb Hemoglobin, ALT Alanine aminotransferase, AST Aspartate aminotransferase.
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exclusively outpatient basis in 85% of the cases. Three
patients needed a brief hospitalization for supportive
care and observation for the following reasons: twice
daily 1.0 Gy WAI (n=1), acute radiation enteritis (n=
1), CTCAE grade 3 anemia requiring blood transfusion
and dehydration (n=1). Electrolyte replenishment was
given in seven patients for hypokalemia (oral or IV).
Late toxicity
All late adverse events are presented in Table 3. No
cancer-free patient has developed late bowel toxicity >
CTC 2. Three patients developed subsequent small
bowel obstruction with 2 requiring surgery and another
patient experienced a sigmoid perforation with florid
peritonitis, all in the context of recurrent intraperitoneal
disease. Fifty percent of the patients experienced a tran-
sient asymptomatic elevation of transaminases with only
one CTCAE grade 3.
Outcomes
The median observation time from completion of all
treatments to death or to the end of the observation
period (January 2012) was 21.5 months (range,
1.7 months-11.5 years). At the time of analysis, 13 pa-
tients were alive and 7 had died. Twelve patients were
alive with no evidence of disease at time of last follow-
up and one patient was alive with progression of disease.
Median follow up for surviving patients was 31.2 months
(range, 3.9 months – 11.5 years). Six patients died of
disease. One patient died of intercurrent illness (pontine
hemorrhage) and the autopsy showed no evidence of
cancer.
For the entire group of patients, KM estimates and
95% confidence intervals for RFS at 1 year were 63%
(38–80%), at 3 years 57% (33-76%). KM estimates and
95% confidence intervals for OS at 1 year were 83% (56-
94%), at 3 years 62% (34-81%) and at 5 years 53% (25-
75%), as shown in Figure 1A-B.
Crude recurrence rates were 2/13 (15%) for EAC, 6/7
(85%) for SP, 1/7 (14%) for stage IIIA, 1/5 (20%) for stage
IIIC and 6/7 (86%) for abdomen-confined stage IVB dis-
ease. None of the 9 (0%) patients with stage III EAC re-
curred, whereas 4/4 (100%) patients with stage IVB SP
recurred. Crude recurrence rates were 2/3 (66%) for
stage IVB EAC and 2/3 (66%) for stage III SP, respect-
ively. One patient with multifocal EAC arising from
endometriosis (no FIGO stage classification available)
has not recurred.
All 3 suboptimally debulked patients experienced re-
currence, all of them being associated with SP histology.
Neither patient with residual disease found on postoper-
ative PET-CT scan experienced a recurrence. Both had
EAC.
The peritoneal cavity was the most frequent site of ini-
tial failure in the form of peritoneal carcinomatosis and
malignant ascites (5/8 recurrences, 62.5%). One patient
experienced a solitary vaginal cuff recurrence 4 months
after end of treatments and was successfully salvaged by
a laparoscopic vaginectomy. Patients with progression
received various regimens of 2nd line therapy, including
iv chemo, ip chemo, targeting agents within phase II
studies, surgery, palliative radiotherapy of distant metas-
tases and/or best supportive care. All recurrences oc-
curred within a year after completion of all treatments
(median: 5 months). Patterns of failure for first recur-
rences are shown in Table 4.
On univariate Cox analysis, stage IVB and SP histology
were the only statistically significant risk factors (at the
p= 0.05 level) associated with worse RFS and OS, as
shown in Figure 1C-F. A multivariate analysis was
performed, but because of the small sample size, no sta-
tistically meaningful results were found. However, stage
and histology seemed to be independently associated
with OS and RFS.
Discussion
Our data show that WAI as part of sequential multimodal
based chemotherapy and radiotherapy is hematologically
feasible and that acute toxicity is manageable in the
context of contemporary supportive care. Tolerability
was reflected in the fact that all patients completed
radiotherapy treatment as planned, without toxicity-
Table 3 Late adverse events (n= 20)
Events Distribution and%
Small bowel obstruction * 3 (15%)
Sigmoid perforation* 1 (5%)
Chronic radiation enteritis and proctitis CTC 1 1 (5%)
Radiation pneumonitis CTC 1 1 (5%)
Vaginal dryness and teleangiectasia 3 (15%)
Dyspareunia 1 (5%)
Urinary urgency CTC 1 1 (5%)
Chronic fatigue 3 (15%)
Chronic neuropathy CTC 2 2 (10%)
Chronic leg oedema 1 (5%)
Tight cellulitis 1 (5%)
Infected lymphocele 1 (5%)
Renal failure** 1 (5%)
Erosive gastritis 1 (5%)
* all in the context of recurrent intraperitoneal recurrent disease.
**Attributed to severe type II diabetic nephropathy, did not receive chemo
because of severe diabetes.
Some patients have >1 adverse event.
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icities occurred during chemotherapy or WAI.
Systemic chemotherapy followed by WAI +/− whole
pelvis boost, extended-field para-aortic boost and/or
vaginal cuff High Dose Rate brachytherapy is an aggres-
sive and potentially morbid treatment regimen. Histor-
ically, several studies have evaluated the toxicity of WAI
as a consolidation treatment after chemotherapy in
Figure 1 Kaplan Meier survival estimates for 20 patients treated with consolidative whole abdomen irradiation after surgery and
chemotherapy for advanced endometrial cancer. A, B:recurrence-free survival (RFS) and overall survival (OS). A, B: Kaplan Meier recurrence-
free survival (RFS) and overall survival (OS) estimates for 20 patients treated with consolidative whole abdomen irradiation after surgery and
chemotherapy for advanced endometrial cancer. C, D: RFS and OS as a function of histology (endometriod vs. papillary serous). E, F: RFS and OS
as a function of FIGO 2009 stage (stage III vs. abdomen-confined stage IV).
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treatment delay in 9–36% and treatment could not be
completed in 4–15% [15-19].
However, little data exist regarding combinations of
chemotherapy and WAI in EC. Two approaches were
reported as being feasible without excessive acute tox-
icity: sequential doxorubicin-cisplatin chemotherapy
followed by WAI and combined radiochemotherapy with
weekly cisplatin and WAI with pelvic boost and optional
para-aortic irradiation [20,21]. However, a more inten-
sive approach with radio-chemotherapy followed by sys-
temic chemotherapy was considered not feasible due to
prohibitive hematologic toxicity [22].
This is, to the best of our knowledge, the first report
on feasibility of WAI after modern TP chemotherapy in
endometrial cancer. A Canadian study reported on a
similar treatment in ovarian cancer [15]. Overall, 34% of
the 29 patients had either grade 3 or 4 acute gastrointes-
tinal or hematologic toxicity. WAI was abandoned be-
cause of myelosuppression in 7% of patients, and
toxicity-related breaks were required in 21% of patients.
The results of this Canadian trial contrast with our re-
sults regarding toxicity and feasibility. This might be
explained by differences in institutional practice in cop-
ing with acute toxicity under treatment. Our policy at
MGH is not to interrupt radiotherapy treatment based
on symptomatic side effects manageable with anti-
emetics, anti-diarrheal agents and supportive I.V. hydra-
tion. Treatment is not interrupted unless absolute
neutrophiles count falls below 900 cells per μL (micro-
litre) or platelets fall below 35,000 per μL of blood.
Late chronic radiation toxicity is a major concern for
WAI, the most common reported being small bowel dam-
age, occurring in approximately 10% of cases [19]. In the
current study, there were 3 cases of small bowel obstruc-
tion, 2 of which required surgery (10%), and one case of
sigmoid perforation, all in the context of tumor recurrence
within the abdomen. Late hepatic toxicity (hepatic veno
occlusive disease) is another rare but potential life-
threatening complication following WAI [19,20]. In the
present study, no patient has developed veno-occlusive
disease or liver necrosis. An elevation of liver enzymes fol-
lowing completion of treatment was observed in 50% of
our cases, mostly transient and asymptomatic, with the ex-
ception of one grade 3 transient case. Still, the inherent
risk of potential lethal liver toxicity emphasizes the neces-
sity of careful liver dose limitation. At MGH, we routinely
use blocking to keep the liver dose ≤22 Gy at 1.0 Gy/frac-
tion and kidney dose ≤18 Gy. However, with ap/pa radio-
therapy technique, using blocks comes at the cost of
target coverage and results in underdosed areas within
the upper abdomen. Intensity-modulated radiotherapy
(IMRT) has been shown to render better coverage of the
entire peritoneal cavity, including the liver capsule and the
diaphragm while effectively sparing the liver parenchyma,
kidneys, and some bone marrow [23,24]. Future efficacy
studies are likely to include this technical refinement.
We identified 20 patients treated over 11 years at MGH;
this is fewer than 2 patients per year. Advanced EC is rare
with few patients suitable for consolidation WAI and facil-
ities offering WAI are even rarer. Our patients were se-
lected because of a perceived high risk for intraperitoneal
recurrence and the absence of known macroscopic re-
sidual tumor after chemotherapy. But despite clear meth-
odological limitations of our study (small sample size,
retrospective study, and modest duration of follow-up)
our data shows a major and statistically significant differ-
ence in outcomes between stage III and IV and between
EAC and SP. The importance of stage and histology is well
documented in the literature [5-7,9,12,13]. Advanced stage
EC is a heterogeneous group and the variety of therapeutic
interventions in the literature - WAI alone, chemotherapy
alone, multimodal treatment with or without WAI as part
of the radiotherapy - makes comparisons difficult. Previ-
ous reports of treatment are summarized in Table 5.
In our study, despite the maximum effort given to the
abdomen, the peritoneal cavity was still the most fre-
quent site of initial failure, with 5/8 recurrences, 2 of
which were associated with additional sites. There are
areas of potential underdosage in the upper abdomen
when using liver and kidney shielding. IMRT has the po-
tential for more homogeneous target coverage and for
conformal dose escalation and might decrease the intra-
abdominal recurrence rate [23,24]. However, this theor-
etical benefit has not yet been clinically proven.
The fact that 2 of 20 patients considered optimally
debulked were found with FDG-avid residual disease on
postoperative PET/CT using contrast enhanced diagnostic
quality CT suggests a need for preoperative imaging in se-
lected patients [25].
Table 4 Patterns of first recurrence (n =8)
Distribution and%
Localization
Inside the abdomen only 6 (75%)
Outside the abdomen only 0 (0%)
Both in- and out the abdomen 2 (25%)
Category
Vaginal cuff recurrence 1 (12.5%)
Peritoneal carcinomatosis 5 (62.5%)
Lymph node 4 (50%)
Pelvic, para-aortic or mesenteric 2 (25%)
Mediastinal or supraclavicular 2 (25%)
Hematogenous (liver, lung) 1 (12.5%)
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adjuvant therapy has been proven for stage III and
abdomen-confined IVB, especially for EAC [10]. How-
ever, the role of WAI in the era of polyagent chemother-
apy treatment remains controversial [12-14].
Conclusions
In summary, we demonstrate that in the contemporary
era, WAI after carboplatin-paclitaxel based chemotherapy
is feasible and safe with both manageable acute and late
toxicities. This approach was associated with favorable
outcomes in our patients with EAC, possibly attribut-
able to radiotherapy benefit. Based on feasibility and
manageable toxicity, it is our hypothesis that WAI coor-
dinated with chemotherapy may warrant prospective in-
vestigation in this patient population. Given the
challenges of accrual, an international study would be
needed. Patients with SP histology did poorly and did
Table 5 Review of literature since 2000: WAI and/or chemotherapy in patients with advanced endometrial cancer
Authors (year) No.
patients
Treatment Design Outcomes Comments Median
follow-up
Smith RS [6] 48 WAI only retrospective 60% 3-y FS (79% for EAC and
47% for PS/CC)
EAC: stage III-IV 37 mo.
77% 3-y OS (89% for EAC and
68% PS/CC)
PS/CC: stage I-IV
Stewart KD [7] 119 WAI only prospective Stage III 5-y OS: 67% for EAC and
40% for SP/CC
Stage III n=81
(68%)
5.8 y
Stage III 5-y DFS: 62% for EAC
and 34% for SP/CC
Dusenbery KE [9] 86 WAI only retrospective 55% 5-y PFS, 46% 10-y PFS, 38%
20-y PFS
Concurrent
cisplatin in 13/86
10 y
57% 5-y OS, 48% 10-y OS, 41%
20-y OS
Sutton G [8] 34 WAI only prospective 38% 5-y PFS for PS Stage I/II PS and CC
only
unknown
54% 5-y PFS for CC
Randall ME [5] 422 Chemo vs. WAI prospective 5-y PFS: 50% for chemo and 38%
for WAI
Adjusted for stage 74 mo.
5-y OS: 55% for chemo and 42%
for WAI
Alvarez Secord A
[11]
356 Chemo vs. RT vs. multi-modality retrospective 3-y PFS: 19% (chemo), 59% (RT),
62% (MM)
39% of WAI in RT
group
38 mo.
3-y OS: 33% (chemo), 70% (RT),
79% (MM)
Fowler JM [20] 31 Multi-modality: chemo+ WAI prospective 53% 5-y PFS Chemo 3 × AC 21 mo.
60% 5-y OS
Rochet N
(present study)
20 Multi-modality: chemo+ WAI retrospective 63% 1-y, 57% 2- and 3-y RFS TP based chemo 31.2 mo.
83% 1-y, 70% 2-y, 62% 3-y, 53%
4-and 5-y OS
Secord A [14] 109 Multi-modality: “sandwich” CRC vs.
RC vs. CR
retrospective 3-y PFS: 69% (CRC), 47% (RC),
52% (CR)
various chemo
(79% TP)
2.8 y
3-y OS: 88% (CRC), 54% (RC), 57%
(CR)
WAI in 13%
Bruzzone M [12] 45 Multi-modality: chemo+ pelvic RT retrospective 30% 9-yPFS 4 × PAC 63 mo.
53% 9-y OS No WAI
Geller MA [13] 42 Multi-modality: “sandwich” chemo
+ pelvic +/− EFRT
prospective 87% 1-y PFS, 71% 3-y PFS, 64% 5-
y PFS
6 × TP 28 mo.
No WAI
95% 1-y OS, 90% 3-y OS, 71% 5-y
OS
Abbreviations: No. Number of, WAI Whole abdomen radiotherapy, Chemo Chemotherapy, EFRT Extended-fields radiotherapy, EAC Endometrioid adenocarcinoma, PS
Papillary serous, CC Clear cell, DFS Disease-free survival, PFS Progression-free survival, OS Overall survival, RFS Recurrence-free survival, MM Multi-modality,
CRC Chemotherapy, interval radiotherapy, subsequent chemotherapy, RC Radiotherapy followed by chemotherapy, CR Chemotherapy followed by radiotherapy,
RT Radiotherapy, TP Carboplatin/paclitaxel, PAC Cisplatin/doxorubicin/cytoxan, AC Doxorubicin/cisplatin.
Rochet et al. Radiation Oncology 2013, 8:236 Page 8 of 9
http://www.ro-journal.com/content/8/1/236not benefit from consolidative treatment as delivered in
this study.
Competing interest
Actual or potential conflicts of interest do not exist. All authors declare that
there are no conflicts of interest. NR is financially supported by a scholarship
from the German Society of Radiation Oncology (DEGRO) for this project.
This study has been presented as a poster during ASTRO’s 2012 Annual
Meeting in Boston (Abstract #2617).
Authors’ contributions
All authors have read and approved the manuscript and agree to its
submission. This manuscript has not been previously published.
Author details
1Department of Radiation Oncology, Massachusetts General Hospital -
Harvard Medical School, 100 Blossom Street, COX3, Boston, MA 02114, USA.
2Department of Radiation Oncology, University of Heidelberg, INF 400,
Heidelberg 69120, Germany.
3Brown University, Warren Alpert Medical
School, Providence, RI, USA.
4Permanent address: Department of Radiation
Oncology, Lausanne University Hospital, Centre Hospitalier Universitaire
Vaudois, Rue du Bugnon 21, Lausanne, Vaud CH-1011, Switzerland.
Received: 7 April 2013 Accepted: 10 September 2013
Published: 14 October 2013
References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin
2012, 62:10–29.
2. Ueda SM, Kapp DS, Cheung MK, et al: Trends in demographic and clinical
characteristics in women diagnosed with corpus cancer and their
potential impact on the increasing number of deaths. Am J Obstet
Gynecol 2008, 198:218–6.
3. Goff BA, Goodman A, Muntz HG, et al: Surgical stage IV endometrial
carcinoma: a study of 47 cases. Gynecol Oncol 1994, 52:237–240.
4. Onda T, Yoshikawa H, Mizutani K, et al: Treatment of node-positive
endometrial cancer with complete node dissection, chemotherapy and
radiation therapy. Br J Cancer 1997, 75:836–1841.
5. Randall ME, Filiaci VL, Muss H, et al: Randomized phase III trial of whole-
abdominal irradiation versus doxorubicin and cisplatin chemotherapy in
advanced endometrial carcinoma: a gynecologic oncology group study.
J Clin Oncol 2006, 4:36–44.
6. Smith RS, Kapp DS, Chen Q, et al: Treatment of high-risk uterine cancer
with whole abdominopelvic radiation therapy. Int J Radiat Oncol Biol Phys
2000, 48:767–778.
7. Stewart KD, Martinez AA, Weiner S, et al: Ten-year outcome including
patterns of failure and toxicity for adjuvant whole abdominopelvic
irradiation in high-risk and poor histologic feature patients with
endometrial carcinoma. Int J Radiat Oncol Biol Phys 2002, 54:527–535.
8. Sutton G, Axelrod JH, Bundy BN, et al: Adjuvant whole abdominal
irradiation in clinical stages I and II papillary serous or clear cell
carcinoma of the endometrium: a phase II study of the gynecologic
oncology group. Gynecol Oncol 2006, 100:349–354.
9. Dusenbery KE, Potish RA, Gold DG, et al: Utility and limitations of
abdominal radiotherapy in the management of endometrial carcinomas.
Gynecol Oncol 2005, 96:635–642.
10. Lee SW, Russell AH, Kinney WK: Whole abdomen radiotherapy for patients
with peritoneal dissemination of endometrial adenocarcinoma. Int J
Radiat Oncol Biol Phys 2003, 56:788–792.
11. Alvarez SA, Havrilesky LJ, Bae-Jump V, et al: The role of multi-modality
adjuvant chemotherapy and radiation in women with advanced stage
endometrial cancer. Gynecol Oncol 2007, 107:285–291.
12. Bruzzone M, Miglietta L, Franzone P, et al: Combined treatment with
chemotherapy and radiotherapy in high-risk FIGO stage III-IV
endometrial cancer patients. Gynecol Oncol 2004, 93:345–352.
13. Geller MA, Ivy JJ, Ghebre R, et al: A phase II trial of carboplatin and
docetaxel followed by radiotherapy given in a “sandwich” method for
stage III, IV, and recurrent endometrial cancer. Gynecol Oncol 2011,
121:112–117.
14. Secord AA, Havrilesky LJ, O’Malley DM, et al: A multicenter evaluation of
sequential multimodality therapy and clinical outcome for the treatment
of advanced endometrial cancer. Gynecol Oncol 2009, 114:442–447.
15. Dinniwell R, Lock M, Pintilie M, et al: Consolidative abdominopelvic
radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for
epithelial ovarian cancer. Int J Radiat Oncol Biol Phys 2005, 62:104–110.
16. Fyles AW, Dembo AJ, Bush RS, et al: Analysis of complications in patients
treated with abdomino-pelvic radiation therapy for ovarian carcinoma.
Int J Radiat Oncol Biol Phys 1992, 22:847–851.
17. Pickel H, Lahousen M, Petru E, et al: Consolidation radiotherapy after
carboplatin-based chemotherapy in radically operated advanced ovarian
cancer. Gynecol Oncol 1999, 72:215–219.
18. Sorbe B: Consolidation treatment of advanced (FIGO stage III) ovarian
carcinoma in complete surgical remission after induction chemotherapy:
a randomized, controlled, clinical trial comparing whole abdominal
radiotherapy, chemotherapy, and no further treatment. Int J Gynecol
Cancer 2003, 13:278–286.
19. Whelan TJ, Dembo AJ, Bush RS, et al: Complications of whole abdominal
and pelvic radiotherapy following chemotherapy for advanced ovarian
cancer. Int J Radiat Oncol Biol Phys 1992, 22:853–858.
20. Fowler JM, Brady WE, Grigsby PW, et al: Sequential chemotherapy and
irradiation in advanced stage endometrial cancer: a gynecologic
oncology group phase I trial of doxorubicin-cisplatin followed by whole
abdomen irradiation. Gynecol Oncol 2009, 112:553–557.
21. Reisinger SA, Asbury R, Liao SY, et al: A phase I study of weekly cisplatin
and whole abdominal radiation for the treatment of stage III and IV
endometrial carcinoma: a gynecologic oncology group pilot study.
Gynecol Oncol 1996, 63:299–303.
22. Soper JT, Reisinger SA, Ashbury R, et al: Feasibility study of concurrent
weekly cisplatin and whole abdominopelvic irradiation followed by
doxorubicin/cisplatin chemotherapy for advanced stage endometrial
carcinoma: a gynecologic oncology group trial. Gynecol Oncol 2004,
95:95–100.
23. Rochet N, Sterzing F, Jensen A, et al: Helical tomotherapy as a new
treatment technique for whole abdominal irradiation. Strahlenther Onkol
2008, 184:145–149.
24. Rochet N, Sterzing F, Jensen AD, et al: Intensity-modulated whole
abdominal radiotherapy after surgery and carboplatin/taxane
chemotherapy for advanced ovarian cancer: phase I study. Int J Radiat
Oncol Biol Phys 2010, 76:1382–1389.
25. Haie-Meder C, Mazeron R, Magne N: Clinical evidence on PET-CT for
radiation therapy planning in cervix and endometrial cancers. Radiother
Oncol 2010, 96:351–355.
doi:10.1186/1748-717X-8-236
Cite this article as: Rochet et al.: Consolidation whole abdomen
irradiation following adjuvant carboplatin-paclitaxel based
chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity
and outcomes. Radiation Oncology 2013 8:236.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rochet et al. Radiation Oncology 2013, 8:236 Page 9 of 9
http://www.ro-journal.com/content/8/1/236